AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie’s blockbuster drug Humira, in a move that will give it more near-term control over the co…
AbbVie’s Ibrutinib (IMBRUVICA) failed to meet its objective in a phase 3 trial DBL3001 in untreated diffuse large B-cell lymphoma (DLBCL) patients.
With eight FDA-approved indications since 2013, Johnson & Johnson and AbbVie’s Imbruvica hasn’t run into many stumbling blocks. But it has hit one in non-Hodgkin lymphoma.
A judge decided a $140 million AndroGel verdict against AbbVie was inconsistent and ordered a new trial in the fall.